US › Healthcare

Geron Corporation (GERN)

US · Healthcare · Biotechnology

$1.34+4.69%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$51.8M
Revenue YoY
+30.9%
Net profit
$-3.6M
Profit YoY
+81.6%
EPS
$-0.00
EPS estimate
$-0.02
Net margin
-7.0%

EPS came in at -0.00 against a street estimate of -0.02 — a beat of 75.5%.

Key statistics

Market cap
$827.6M
Forward P/E
0.0
P/B
3.61
Book value
$0.36
EPS (TTM)
$-0.11
52-week high
$2.01
52-week low
$1.04
50-day MA
$1.32
200-day MA
$1.40
Beta
0.60

Analyst view

Analysts rate Geron Corporation a buy (6 buy, 3 hold, 0 sell out of 9) with an average price target of $4.25.

Shareholding

Insiders
0.08%
Institutions
79.92%

Largest institutional holders

FundStake
RA Capital Management, LLC9.94%
BlackRock Inc7.38%
Soleus Capital Management, L.P.6.47%
Vanguard Group Inc5.56%
Deep Track Capital, LP4.94%
State Street Corp4.75%
Vanguard Capital Management, LLC4.16%
Citadel Advisors Llc3.36%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Geron Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.